Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.55 |
| ▸ | CPS1 | P31327 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448741 | 0.92 | ATR (0.48) | L3MBTL3CPS1ATRPIK3CAMTOR | |
| SCHEMBL1449080 | 0.92 | ATR (0.48) | L3MBTL3CPS1ATRPIK3CAMTOR | |
| SCHEMBL1448739 | 0.92 | ATR (0.48) | L3MBTL3CPS1ATRPIK3CAMTOR | |
| SCHEMBL24632521 | 0.85 | L3MBTL3 (0.56) | L3MBTL3CPS1L3MBTL1ATRPIK3CA | |
| SCHEMBL2797831 | 0.85 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1PIK3CAMTORHPGD | |
| SCHEMBL15285918 | 0.84 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1ATRPIK3CAMTOR | |
| SCHEMBL30198624 | 0.84 | L3MBTL3 (0.55) | L3MBTL3CPS1L3MBTL1ATRPIK3CA | |
| SCHEMBL21245833 | 0.84 | L3MBTL3 (0.55) | L3MBTL3CPS1L3MBTL1ATRPIK3CA | |
| SCHEMBL21267575 | 0.82 | L3MBTL3 (0.52) | L3MBTL3CPS1L3MBTL1ATRPIK3CA | |
| SCHEMBL25085646 | 0.82 | L3MBTL3 (0.52) | L3MBTL3CPS1L3MBTL1ATRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | L3MBTL3 4289/4885CPS1 3296/4885L3MBTL1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.